Kinnate Biopharma Inc (KNTE) - News Archive

Showing 2 of 2 results.

Kinnate Biopharma Inc Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre LaboratoriesSAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 - Kinnate Biopharma Inc. (Nasdaq: KNTE), a clinica...

Mar 1, 2024 • Major Pharmaceutical Preparations Industry Financing Agreement

Merger of Kinnate Biopharma Inc. and XOMA Corporation Accelerates Precision Oncology Advancements

Kinnate Biopharma Inc Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per ShareSan Francisco and San Diego - In a significant d...

Feb 16, 2024 • Major Pharmaceutical Preparations Industry Merger and Acquisition